The GLP-1 Story Everyone Wants to Believe

We’re being told that new GLP-1 drugs are about to solve everything—obesity, diabetes, even our runaway healthcare costs. It’s a nice, simple story. It’s also wrong. While these drugs will certainly make pharma companies a fortune, they aren’t the miracle cure we’ve been promised. They won’t transform public health, save insurers money, or deliver the endless growth Wall Street is dreaming of. The reality is, a lot of people stop taking them, insurers are balking at the price, and our whole way of life creates chronic disease far faster than any drug can fix it. The hype has simply gotten way ahead of the facts.

The Fairy Tale Everyone Wants to Believe

GLP-1s are the perfect story for our times. They promise weight loss without us having to confront our broken food system. They promise better health without us having to change our lifestyles. They even promise to lower healthcare costs without lowering drug prices.

For Wall Street, it’s a gold rush. For marketers, it’s a cultural moment. For the healthcare industry, it’s being sold as the inevitable future. But we should know by now that what’s inevitable isn’t always sustainable.

The Reality No One Wants to Talk About: People Quit

The drug companies love to celebrate every new prescription, but they’re a lot quieter about how many people abandon the treatment. In the real world, people stop taking these drugs. They stop because of the nausea, the stomach issues, the exhaustion, or just the burnout of constant injections. They stop when their insurance changes and they’re suddenly facing a massive bill. They stop when the weight loss plateaus. And many stop simply because they never signed up for a lifetime of medication.

A drug that only works as long as you’re on it—and that most people don’t stay on—is not a foundation for a health revolution. It’s a revolving door.

The Pushback from People Paying the Bills

The whole sales pitch rests on the idea that insurance companies will eventually just get used to the cost and cover these drugs for everyone. Don’t bet on it.

Employers, insurers, and government programs are all doing the math and realizing they simply can’t afford to put millions of people on these drugs forever at today’s prices. So they’re quietly putting up roadblocks: stricter requirements for who can get them, limits on how long they’ll cover them, and higher copays that push the cost back onto patients. This isn’t a temporary glitch; it’s the system putting the brakes on. You can’t market your way out of a budget crisis.

Doctors can’t just write an Rx; There needs to be a follow-up

In focus groups, a large majority said their physicians did not follow up after prescribing a GLP-1. This is unacceptable. Patients need to understand that GLP-1s are not a “magic shot” and that they need to amend their eating patterns. In addition, we heard that some patients expected miracle results (fast weight loss). GLP-1s are only as good as the education of the people who take them.

Weight Loss Isn’t Health Reform

These drugs are being framed as a shortcut to fix decades of failed public health policy. That’s a tempting idea, but it’s deeply misleading. Losing weight doesn’t fix the fact that our food is overwhelmingly ultra-processed, that healthy diets are a luxury for many, or that our jobs chain us to our desks. A weekly shot can’t undo the metabolic damage caused by chronic stress.

At best, GLP-1s are a Band-Aid, managing the symptoms of a society that is designed to make us sick. At worst, they create the illusion of progress while the root causes go untouched. You can’t medicate your way out of a problem that our culture churns out every single day.

That “Huge Market” Is a Fantasy

Every glowing investor presentation features a slide showing a massive potential market of tens of millions of “eligible” patients. But in the real world, “eligible” is meaningless.

The real market is the number of people who can get insurance to cover it, who can actually afford the long-term costs, who can tolerate the side effects, and who will stick with the treatment year after year. Once you factor in those realities, that giant number shrinks—fast. What’s left is still a big market, but it’s nowhere near the fantasy being sold to investors.

The Business Model Depends on Failure

Here’s the uncomfortable irony: for these drugs to remain a blockbuster success, we have to keep failing at public health. If our food systems improved, demand would fall. If employers invested in meaningful wellness programs, fewer people would need them. The business model isn’t built on solving the problem; it’s built on monetizing its symptoms. That’s a great way to generate revenue, but a terrible way to build a healthier society.

This Ends in a Price War, Not a Revolution

Eventually, this won’t be a miracle market. It’ll just be a market. As more competitors launch similar drugs, insurance companies will see them as interchangeable. That means pricing power will decline, access will tighten, and the future of GLP-1s will look less like a revolution and more like a familiar story of formulary battles and rebate negotiations. That’s not a transformation; that’s just business as usual.

The Simple Truth

Let’s be clear about what these drugs are. They are powerful, effective medications. They are not a cure. They are not healthcare reform. And they are not a limitless growth opportunity.

They are a highly profitable response to a system that refuses to fix itself. Any analyst who ignores why people stop taking them, why insurers are pushing back, and why our society creates these problems in the first place isn’t doing analysis—they’re doing marketing. And sooner or later, reality always catches up with marketing.

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply